Chun R Ding bought $1.0M of GRAIL (GRAL)
Executed Oct 1 2024, disclosed Oct 10 2024, 9 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Oct 10 2024), the stock returned +15.4% (delay-adjusted); from the execution session (Oct 1 2024), -5.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Chun R Ding (10% owner) filed 2 Form 4 reports in the past 24 months (1 purchase, 1 sale, 1 filed past the two-business-day deadline), most often in GRAIL, Inc. (GRAL). Across 1 priced purchase filing, the average 21-session return was -5.0% from execution and +15.4% from disclosure (delay-adjusted; derived). The largest single filing was $16.8M of GRAL (339,800 sh across 3 lots, as filed), executed Jul 1 2025.
Healthcare · GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and int…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→339,800 sh across 3 lots
Exec Jul 1 2025
Filed Jul 3 2025 · 5:30 PM ET